SCHEMBL12371067

SCHEMBL12371067

CC(=O)Oc1ccc(C2CCC(C3CC(=O)O3)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
LMNA P02545 3/20 0.39
RAB9A P51151 2/20 0.39
GLA P06280 3/20 0.38
MAPT P10636 4/20 0.37
GAA P10253 3/20 0.37
POLB P06746 2/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PKM P14618 1/20 0.36
HSD17B10 Q99714 5/20 0.36
ALDH1A1 P00352 5/20 0.36
HPGD P15428 2/20 0.36
HTT P42858 2/20 0.36
CACNA1B Q00975 2/20 0.36
APBA1 Q02410 2/20 0.36
ATM Q13315 2/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371048 0.83 ALDH1A1 (0.44) LMNARAB9AMAPTHSD17B10ALDH1A1
SCHEMBL12371032 0.82 NOTUM (0.38) RAB9APOLBESR1
SCHEMBL4443112 0.82 LMNA (0.55) KDM4ENPSR1LMNARAB9AGLA
SCHEMBL11221386 0.80 LMNA (0.46) KDM4ENPSR1LMNARAB9AGLA
SCHEMBL12371041 0.80 ALDH1A1 (0.43) KDM4ERAB9AMAPTGAAHSD17B10
SCHEMBL23142716 0.79 ESR2 (0.50) KDM4ENPSR1LMNARAB9AGLA
SCHEMBL12371008 0.78 HTT (0.46) KDM4ERAB9AGLAMAPTGAA
SCHEMBL12371000 0.78 MAP1LC3B (0.40) LMNAGLAMAPTPOLBALDH1A1
SCHEMBL2273714 0.77 MAP1LC3B (0.39) LMNAGLAMAPTPOLBALDH1A1
SCHEMBL2271030 0.77 MAP1LC3B (0.39) LMNAGLAMAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2020407-B1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF JNC CORP (JP) 2013-07-03 EP disclosed
US-7999123-B2 2-oxetanone derivative and process for production thereof JNC CORPORATION (JP) 2011-08-16 US disclosed
US-7999123-B2 2-oxetanone derivative and process for production thereof JNC CORPORATION (JP) 2011-08-16 US disclosed
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF CHISSO CORPORATION (JP) 2009-11-05 US disclosed
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF CHISSO CORPORATION (JP) 2009-11-05 US disclosed
EP-2020407-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF Chisso Corporation (JP) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF OGDH, OXGR1, OXER1 KDM4E 408/4885NPSR1 3790/4885LMNA 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.